{"id":7507,"date":"2017-11-03T09:38:04","date_gmt":"2017-11-03T09:38:04","guid":{"rendered":"https:\/\/www.nicox.com\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\/"},"modified":"2017-11-03T09:38:04","modified_gmt":"2017-11-03T09:38:04","slug":"conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\/","title":{"rendered":"Conf\u00e9rence t\u00e9l\u00e9phonique le 3 novembre 2017 suite \u00e0 l\u2019approbation de VYZULTA (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% par la FDA am\u00e9ricaine     le 2 novembre 2017"},"content":{"rendered":"<p>Sophia Antipolis, France<\/p>\n<p><strong>Nicox S.A.<\/strong> (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, <strong>tiendra une conf\u00e9rence t\u00e9l\u00e9phonique aujourd&rsquo;hui \u00e0 17h00 suite \u00e0 l&rsquo;annonce de l\u2019approbation de VYZULTA\u00ae par la FDA am\u00e9ricaine.<\/strong><\/p>\n<p>Pour acc\u00e9der \u00e0 la conf\u00e9rence t\u00e9l\u00e9phonique, <strong>merci de composer +33 (0)1 76 77 28 19 (France) et le code de conf\u00e9rence 2434314\u2260<\/strong>. L\u2019acc\u00e8s \u00e0 la conf\u00e9rence t\u00e9l\u00e9phonique sera disponible 10 minutes avant son commencement.<\/p>\n<p>Une pr\u00e9sentation au format PDF sera disponible et archiv\u00e9e sur le site internet de la Soci\u00e9t\u00e9 (<a href=\"https:\/\/www.nicox.com\">www.nicox.com<\/a>) \u00e0 la rubrique Pr\u00e9sentations et \u00c9v\u00e8nements.<\/p>\n<p>Un enregistrement de la conf\u00e9rence t\u00e9l\u00e9phonique sera disponible, du 3 novembre \u00e0 partir de 19h00 jusqu&rsquo;au 10 novembre, sur le site internet de la Soci\u00e9t\u00e9 (www.nicox.com) \u00e0 la rubrique Pr\u00e9sentations et \u00c9v\u00e8nements ou par t\u00e9l\u00e9phone au +33 (0)1 70 48 00 94 (code d\u2019acc\u00e8s 2434314#).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France Nicox S.A. (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, tiendra une conf\u00e9rence t\u00e9l\u00e9phonique aujourd&rsquo;hui \u00e0 17h00 suite \u00e0 l&rsquo;annonce de l\u2019approbation de VYZULTA\u00ae par la FDA am\u00e9ricaine. Pour acc\u00e9der \u00e0 la conf\u00e9rence t\u00e9l\u00e9phonique, merci de composer +33 (0)1 76 77 28 19 (France) et le code de [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[16,31],"tags":[],"class_list":["post-7507","post","type-post","status-publish","format-standard","hentry","category-actualites-et-media","category-evenements"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Conf\u00e9rence t\u00e9l\u00e9phonique le 3 novembre 2017 suite \u00e0 l\u2019approbation de VYZULTA (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% par la FDA am\u00e9ricaine   le 2 novembre 2017 - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Conf\u00e9rence t\u00e9l\u00e9phonique le 3 novembre 2017 suite \u00e0 l\u2019approbation de VYZULTA (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% par la FDA am\u00e9ricaine   le 2 novembre 2017 - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France Nicox S.A. (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, tiendra une conf\u00e9rence t\u00e9l\u00e9phonique aujourd&rsquo;hui \u00e0 17h00 suite \u00e0 l&rsquo;annonce de l\u2019approbation de VYZULTA\u00ae par la FDA am\u00e9ricaine. Pour acc\u00e9der \u00e0 la conf\u00e9rence t\u00e9l\u00e9phonique, merci de composer +33 (0)1 76 77 28 19 (France) et le code de [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2017-11-03T09:38:04+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Conf\u00e9rence t\u00e9l\u00e9phonique le 3 novembre 2017 suite \u00e0 l\u2019approbation de VYZULTA (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% par la FDA am\u00e9ricaine le 2 novembre 2017\",\"datePublished\":\"2017-11-03T09:38:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\\\/\"},\"wordCount\":178,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s et M\u00e9dia\",\"Ev\u00e8nements\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\\\/\",\"name\":\"Conf\u00e9rence t\u00e9l\u00e9phonique le 3 novembre 2017 suite \u00e0 l\u2019approbation de VYZULTA (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% par la FDA am\u00e9ricaine le 2 novembre 2017 - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2017-11-03T09:38:04+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Conf\u00e9rence t\u00e9l\u00e9phonique le 3 novembre 2017 suite \u00e0 l\u2019approbation de VYZULTA (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% par la FDA am\u00e9ricaine   le 2 novembre 2017 - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\/","og_locale":"fr_FR","og_type":"article","og_title":"Conf\u00e9rence t\u00e9l\u00e9phonique le 3 novembre 2017 suite \u00e0 l\u2019approbation de VYZULTA (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% par la FDA am\u00e9ricaine   le 2 novembre 2017 - Nicox","og_description":"Sophia Antipolis, France Nicox S.A. (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, tiendra une conf\u00e9rence t\u00e9l\u00e9phonique aujourd&rsquo;hui \u00e0 17h00 suite \u00e0 l&rsquo;annonce de l\u2019approbation de VYZULTA\u00ae par la FDA am\u00e9ricaine. Pour acc\u00e9der \u00e0 la conf\u00e9rence t\u00e9l\u00e9phonique, merci de composer +33 (0)1 76 77 28 19 (France) et le code de [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\/","og_site_name":"Nicox","article_published_time":"2017-11-03T09:38:04+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\/"},"author":{"name":"","@id":""},"headline":"Conf\u00e9rence t\u00e9l\u00e9phonique le 3 novembre 2017 suite \u00e0 l\u2019approbation de VYZULTA (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% par la FDA am\u00e9ricaine le 2 novembre 2017","datePublished":"2017-11-03T09:38:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\/"},"wordCount":178,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s et M\u00e9dia","Ev\u00e8nements"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\/","url":"https:\/\/www.nicox.com\/fr\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\/","name":"Conf\u00e9rence t\u00e9l\u00e9phonique le 3 novembre 2017 suite \u00e0 l\u2019approbation de VYZULTA (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% par la FDA am\u00e9ricaine le 2 novembre 2017 - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2017-11-03T09:38:04+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/conference-telephonique-le-3-novembre-2017-suite-lapprobation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-par-la-fda-americaine-le-2-novembre-2017\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7507","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7507"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7507\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7507"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7507"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}